Standard BioTools Past Earnings Performance
Past criteria checks 0/6
Standard BioTools's earnings have been declining at an average annual rate of -32.2%, while the Life Sciences industry saw earnings growing at 27.2% annually. Revenues have been growing at an average rate of 13% per year.
Key information
-32.2%
Earnings growth rate
-3.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 13.0% |
| Return on equity | -26.2% |
| Net Margin | -159.5% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Standard BioTools makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 82 | -130 | 126 | 0 |
| 30 Jun 23 | 101 | -141 | 150 | 0 |
| 31 Mar 23 | 95 | -139 | 158 | 0 |
| 31 Dec 22 | 98 | -109 | 155 | 0 |
| 30 Sep 22 | 102 | -83 | 146 | 0 |
| 30 Jun 22 | 80 | -92 | 118 | 0 |
| 31 Mar 22 | 86 | -82 | 96 | 0 |
| 31 Dec 21 | 82 | -88 | 78 | 0 |
| 30 Sep 21 | 87 | -73 | 58 | -2 |
| 30 Jun 21 | 81 | -39 | 46 | 0 |
| 31 Mar 21 | 68 | -45 | 40 | 0 |
| 31 Dec 20 | 56 | -53 | 37 | 0 |
| 31 Dec 19 | 32 | -57 | 33 | 0 |
Quality Earnings: 76X0 is currently unprofitable.
Growing Profit Margin: 76X0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 76X0 is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare 76X0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 76X0 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.2%).
Return on Equity
High ROE: 76X0 has a negative Return on Equity (-26.25%), as it is currently unprofitable.